Outset Medical (OM) to Release Quarterly Earnings on Wednesday

Outset Medical (NASDAQ:OM) is anticipated to announce its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $28.90 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Outset Medical Price Performance

Shares of OM opened at $5.04 on Wednesday. Outset Medical has a 1-year low of $3.10 and a 1-year high of $21.98. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. The stock has a market cap of $91.48 million, a PE ratio of -0.39 and a beta of 2.08. The firm has a fifty day moving average price of $4.42 and a 200 day moving average price of $10.08.

Insider Activity at Outset Medical

In other news, EVP Marc Nash sold 5,375 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $27,520.00. Following the completion of the transaction, the executive vice president owned 42,785 shares of the company’s stock, valued at $219,059.20. The trade was a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28. Following the sale, the chief executive officer owned 107,823 shares in the company, valued at approximately $552,053.76. This trade represents a 9.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 35,989 shares of company stock valued at $180,073. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in shares of Outset Medical by 662.8% in the second quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock valued at $162,000 after purchasing an additional 7,344 shares during the period. Legal & General Group Plc purchased a new position in Outset Medical during the second quarter worth about $34,000. Rhumbline Advisers acquired a new stake in Outset Medical in the 2nd quarter worth about $499,000. New York State Common Retirement Fund purchased a new stake in Outset Medical in the 2nd quarter valued at about $108,000. Finally, Quantbot Technologies LP acquired a new position in shares of Outset Medical during the 2nd quarter valued at about $152,000.

Analysts Set New Price Targets

Several research firms recently commented on OM. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a report on Wednesday, December 17th. Stifel Nicolaus decreased their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 7th. BTIG Research reissued a “buy” rating and issued a $17.00 target price on shares of Outset Medical in a report on Tuesday, December 16th. Finally, Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.67.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.